Zhou Shuai, Huang Yanmei, Liang Bingshao, Dong Hui, Yao Shuwen, Chen Yinshuang, Xie Yongqiang, Long Yan, Gong Sitang, Zhou Zhenwen
Guangzhou Women and Children's Medical Center, Guangzhou Medical University, No. 318 Renminzhong Road, Yuexiu, Guangzhou, Guangdong 510120, People's Republic of China.
Translational Medicine Center, Guangdong Women and Children Hospital, No. 521 Xingnan Avenue, Panyu district, Guangzhou, Guangdong 511400, People's Republic of China.
FEMS Microbiol Lett. 2017 Jan;364(2). doi: 10.1093/femsle/fnw288. Epub 2017 Jan 12.
Previous epidemiologic studies have demonstrated an inverse association between Helicobacter pylori infection and the frequency of allergic asthma. The neutrophil-activating protein (NAP) of H. pylori has been identified as a modulator possessing anti-Th2 inflammation activity. Here, we sought to determine whether systemic or mucosal pre-administration of recombinant H. pylori NAP (rNAP) could prevent ovalbumin (OVA)-induced allergic asthma in mice.
Mice were exposed to purified rNAP through intraperitoneal injection or inhalation and then sensitized with OVA. Following a challenge with aerosolized OVA, the bronchoalveolar lavage fluid (BALF) cell count, lung tissue histology, BALF cytokines and serum IgE were evaluated.
Both intraperitoneal injection and inhalation of rNAP prior to OVA sensitization significantly reduced eosinophil accumulation and inflammatory infiltration in lung tissue in OVA-induced asthma mice; eosinophils were reduced in the BALF of rNAP-treated mice. In addition, IL-4 and IL-13 levels were lower (P < 0.01), IL-10 and IFN-γ levels were higher (P < 0.01) and IgE serum levels were lower (P < 0.01) in the treated groups compared to the control group.
Systemic and mucosal pre-administration of rNAP could suppress the development of OVA-induced asthma in mice; rNAP may be utilized as part of novel strategies for the prevention or treatment of allergic diseases.
既往流行病学研究表明幽门螺杆菌感染与过敏性哮喘的发病频率呈负相关。幽门螺杆菌的中性粒细胞激活蛋白（NAP）已被确定为具有抗Th2炎症活性的调节剂。在此，我们旨在确定重组幽门螺杆菌NAP（rNAP）的全身或黏膜预给药是否能预防卵清蛋白（OVA）诱导的小鼠过敏性哮喘。
通过腹腔注射或吸入使小鼠接触纯化的rNAP，然后用OVA致敏。在用雾化OVA激发后，评估支气管肺泡灌洗液（BALF）细胞计数、肺组织组织学、BALF细胞因子和血清IgE。
在OVA致敏前腹腔注射和吸入rNAP均显著减少了OVA诱导的哮喘小鼠肺组织中的嗜酸性粒细胞积聚和炎症浸润；rNAP处理小鼠的BALF中嗜酸性粒细胞减少。此外，与对照组相比，治疗组的IL-4和IL-13水平较低（P<0.01），IL-10和IFN-γ水平较高（P<0.01），IgE血清水平较低（P<0.01）。
rNAP的全身和黏膜预给药可抑制OVA诱导的小鼠哮喘的发展；rNAP可作为预防或治疗过敏性疾病新策略的一部分。
